Zynex to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
ENGLEWOOD, Colo., Aug. 28, 2018 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), An innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, and neurological diagnostics, today announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. LLC. The conference is being held September 4-6, 2018 at the St. Regis Hotel in New York City.
Thomas Sandgaard, Chief Executive Officer of Zynex, will provide an overview of the Company's business in a presentation scheduled on Thursday, September 6, 2018 at 12:05 pm EDT. Management will also be meeting with members of the investment community during one-on-one meetings.
Event: 20th Annual Rodman & Renshaw Global Investment Conference
Date: September 6, 2018
Time: 12:05 pm (Eastern Time)
Location: Louis XVI B (2nd floor) St. Regis Hotel in New York City
A live audio webcast and copy of the presentation can be accessed through the following link
or through the "Investors" section of the Company's website at www.zynex.com. The webcast replay will remain available for 90 days following the live presentation.
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2017 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.
Investor Relations contact:
Amato and Partners, LLC
100 Park Avenue, 16th Floor
New York, NY 10017